Shots:
- GSK has entered into a worldwide exclusive license agreement with Empirico to develop & commercialize EMP-012
- As per the deal,Empirico will lead P-I development of EMP-012, following which GSK will take over global development, regulatory filings, & commercialization, with Empirico receiving $85M upfront, ~$660M in development, regulatory & commercial milestones, & tiered royalties on global net sales
- EMP-012, a selective siRNA oligonucleotide, is in P-I for COPD & has potential to expand to other inflammatory respiratory diseases, offering GSK monotx. & combination opportunities across its COPD portfolio
Ref: GSK | Image: GSK & Empirico | Press Release
Related News:- Incyte Partners with Enable Injections for enFuse On-Body Delivery System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
